Related Experiment Video

Updated: Mar 18, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E Miller1, Rachel Brough1, Ilirjana Bajrami1

  • 1The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom. Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

Molecular Cancer Therapeutics
|July 2, 2016
PubMed

Insights

New research reveals a synthetic lethal interaction between dasatinib and ARID1A mutations in ovarian clear cell carcinomas. This finding suggests dasatinib as a potential targeted therapy for ARID1A-mutant OCCC, addressing limited treatment options.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian clear cell carcinomas (OCCC) have limited treatment options and poor response to chemotherapy.
  • Targeted therapies are urgently needed for OCCC, particularly for tumors with specific genetic drivers.

Purpose of the Study:

  • To identify novel synthetic lethal interactions for OCCC treatment.
  • To investigate the therapeutic potential of dasatinib in ARID1A-mutant OCCC.

Main Methods:

  • High-throughput drug screening in OCCC cell models.
  • In vitro and in vivo validation of synthetic lethality.
  • siRNA screens and kinase profiling to identify drug targets.

Main Results:

  • A synthetic lethal interaction was identified between dasatinib and ARID1A mutations in OCCC.
  • ARID1A-deficient cells showed increased sensitivity to dasatinib, leading to G1-S cell-cycle arrest.
  • ARID1A-mutant OCCC cells demonstrated addiction to YES1, a target of dasatinib.

Conclusions:

  • Dasatinib exhibits synthetic lethality with ARID1A deficiency in OCCC.
  • Dasatinib shows promise as a targeted therapy for patients with ARID1A-mutant OCCC.
  • Targeting YES1 could be a viable strategy for OCCC treatment.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K